DekaBank Deutsche Girozentrale decreased its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 0.4% during the second quarter, Holdings Channel reports. The institutional investor owned 114,050 shares of the biopharmaceutical company’s stock after selling 443 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Alexion Pharmaceuticals were worth $14,055,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. C WorldWide Group Holding A S raised its position in Alexion Pharmaceuticals by 192.7% in the second quarter. C WorldWide Group Holding A S now owns 113,427 shares of the biopharmaceutical company’s stock valued at $13,801,000 after buying an additional 74,676 shares in the last quarter. First Trust Advisors LP raised its position in Alexion Pharmaceuticals by 14.4% in the second quarter. First Trust Advisors LP now owns 327,953 shares of the biopharmaceutical company’s stock valued at $39,902,000 after buying an additional 41,384 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in Alexion Pharmaceuticals by 14.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 795,572 shares of the biopharmaceutical company’s stock valued at $96,798,000 after buying an additional 97,659 shares in the last quarter. Canada Pension Plan Investment Board raised its position in Alexion Pharmaceuticals by 35.9% in the second quarter. Canada Pension Plan Investment Board now owns 351,796 shares of the biopharmaceutical company’s stock valued at $42,803,000 after buying an additional 92,866 shares in the last quarter. Finally, Cigna Investments Inc. New raised its position in Alexion Pharmaceuticals by 21.0% in the second quarter. Cigna Investments Inc. New now owns 11,150 shares of the biopharmaceutical company’s stock valued at $1,357,000 after buying an additional 1,936 shares in the last quarter. 95.14% of the stock is currently owned by institutional investors and hedge funds.

Alexion Pharmaceuticals, Inc. (ALXN) opened at 132.93 on Friday. The firm has a market cap of $29.67 billion, a P/E ratio of 57.65 and a beta of 1.41. Alexion Pharmaceuticals, Inc. has a 12 month low of $96.18 and a 12 month high of $145.42. The stock has a 50 day moving average of $129.36 and a 200-day moving average of $122.92.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.48. The firm had revenue of $912 million during the quarter, compared to analyst estimates of $846.15 million. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The business’s quarterly revenue was up 21.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.13 earnings per share. Equities research analysts predict that Alexion Pharmaceuticals, Inc. will post $5.60 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/08/13/dekabank-deutsche-girozentrale-sells-443-shares-of-alexion-pharmaceuticals-inc-alxn.html.

Several equities analysts have commented on ALXN shares. Morgan Stanley raised shares of Alexion Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $101.08 to $138.00 in a report on Thursday, May 25th. Barclays PLC reissued an “overweight” rating and issued a $155.00 target price on shares of Alexion Pharmaceuticals in a report on Tuesday, May 9th. Cowen and Company reissued an “outperform” rating and issued a $180.00 target price on shares of Alexion Pharmaceuticals in a report on Friday, April 28th. J P Morgan Chase & Co lowered shares of Alexion Pharmaceuticals from an “overweight” rating to a “neutral” rating in a report on Tuesday, May 23rd. Finally, Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, April 18th. Five equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and three have given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $156.89.

In other Alexion Pharmaceuticals news, CEO Ludwig Hantson purchased 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 14th. The stock was bought at an average price of $116.72 per share, with a total value of $1,167,200.00. Following the completion of the purchase, the chief executive officer now directly owns 38,725 shares of the company’s stock, valued at approximately $4,519,982. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bros. Advisors Lp Baker purchased 1,348,955 shares of the company’s stock in a transaction that occurred on Wednesday, June 14th. The stock was acquired at an average cost of $116.32 per share, with a total value of $156,910,445.60. The disclosure for this purchase can be found here. In the last three months, insiders have bought 2,019,734 shares of company stock valued at $235,606,846. Insiders own 4.35% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.